Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial
ConclusionsIn this study, CAB LA was well tolerated at the doses and dosing intervals used. ISRs were common, but infrequently led to product discontinuation. CAB LA 600 mg every 8 weeks met pharmacokinetic targets for both male and female study participants. The safety and pharmacokinetic results observed support the further development of CAB LA, and efficacy studies of CAB LA for HIV treatment and prevention are in progress. Trial registrationClinicalTrials.gov Registry: ClinicalTrials.gov Trial number: NCT02178800.
Source: PLoS Medicine - Category: Internal Medicine Authors: Raphael J. Landovitz Source Type: research
More News: African Health | Brazil Health | Burns | Internal Medicine | Laboratory Medicine | Malawi Health | South Africa Health | STDs | Study | USA Health